1. Do you currently offer a biomarker testing for the following, as of the beginning of 2018?
PD-L1 in NSCLC
ALK in NSCLC
BRAF in Melanoma
2. Is predictive biomarker testing conducted at the same lab (or similar location such as in same building) as the initial cytological and histological (H&E stain) assessment, or is this done at a different site?
IHC
FISH /ISH/ NGS / PCR
3. Is biomarker testing performed reflexively or upon request for the following biomarkers?
PD-L1 in NSCLC
ALK for NSCLC
BRAF in Melanoma
4. Which of the following biomarkers are assessed in lung cancer patients in your laboratory? (please select all that apply)
5. Which of the following testing platforms are used at this this laboratory?
6. What IHC staining platform(s) are used in the laboratory for biomarker testing? (please select all that apply)
7. What type of test does the institution prefer to use for biomarker-predictive IHCs?
What is the main factor in this decision?
8. Does your lab / trust seek separate reimbursement from NHS under the “high-cost medicines and tests” provision for biomarker tests that have been excluded from tariff?
9. What is the number of samples being tested (or sent-out) are tested for the following biomarkers?
ALK
EGFR
PD-L1
BRAF
10. Where are archived tissues from lung cancer patients stored?
11. If on-site; how long are tissues stored on site until transferred to other storage facility?
12. What is the typical turn-around time from tissue/specimen extraction to the report of biomarker testing results in lung cancer patients?
13. How are the following biomarker testing funded at your lab?
